The global head lice treatment market is estimated at USD 937.44 million in 2021. It is expected to reach USD 1,329. 47 million by 2027, registering a CAGR of 6.24% from 2022 to 2027. The emergence of the COVID-19 pandemic is an unprecedented health concern and has had a significant impact on the growth of the market.
New York, May 03, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the publication of the report “Lice Treatment Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” – https://www .reportlinker .com/p06272906/?utm_source=GNW
During the Covid-19 pandemic, the distribution of ivermectin has increased in retail pharmacies and there has been an increase in the number of patients for the treatment of lice in various clinics in the United States. For example, according to the article published by the Centers for Disease Control and Prevention (CDC) in August 2021 titled “Rapid Rise in Ivermectin Prescriptions and Reports of Serious Illness Associated with Use of Ivermectin-Containing Products ivermectin to prevent or treat COVID-19,” the distribution of ivermectin from outpatient retail pharmacies in the United States during COVID-19 has increased from an average of 3,600 prescriptions per week before the pandemic (March 16, 2019 to March 13, 2020) to a peak of 39,000 prescriptions during the week ending January 8, 2021. Additionally, the July 2020 article titled “Lice Clinics of America – Bakersfield Report Lice Activity Augmentation during Pandemic” reports that , Lice Clinics of America, Bakersfield, saw a 37% increase in head lice treatments from April to May 2020, amid the COVID-19 pandemic. Additionally, in October 2021, the Lice Clinic of America announced that the company had reached a total of 750,000 successful head lice treatments and the milestone was reached after a second year of the COVID-19 pandemic. So, although COVID-19 has caused a shortage of essential commodities and created obstacles, the treatment of lice has played an important role during COVID-19. Thus, the COVID-19 pandemic has had a positive impact on the growth of the studied market and is expected to drive the growth of the market over the forecast period.
The growth of the market can be attributed to factors such as increasing prevalence of lice infestation and easy availability of lice treatment products. For example, according to the Pediculosis chapter updated in February 2022 in the National Center for Biotechnology Information (NCBI), it is stated that pediculosis or lice infestation affects hundreds of millions of people every year in the world. world and that it has been reported in all countries and in all socio-economic classes. .
Moreover, according to a study published in May 2021 entitled “Head Lice at School: Traditional Medicine and Community Engagement”, the prevalence of head lice in poor rural communities and urban slums is estimated between 28% and 43% in Brazil. , respectively. The study also suggests that the prevalence in different schools in Norway ranged from 0% to 7.14%, although 36.43% of the households that participated in the study had already experienced a head lice infestation. Thus, the prevalence indicates the growing demand for head lice treatment. Moreover, according to a United Nations survey in 2019, the number of children under the age of 14 is expected to cross 2.02 billion and reach 2.06 billion by 2050. This huge number of people prone to infestation by lice indicates the rising prevalence of lice infestation, thereby driving the growth of the market.
However, a major factor restraining the growth of the market studied is the lack of awareness and declining healthcare expenditure in developing countries.
Main market trends
The permethrin segment is expected to hold a significant share of the market
The permethrin segment is expected to hold a major share of the market. Permethrin is used to treat scabies in adults and children 2 months and older. Over-the-counter permethrin is used to treat lice (small insects that attach to the skin on the head) in adults and children 2 months and older. Permethrin belongs to a class of medications called scabicides and pediculicides. It works by killing lice and mites.
According to the study “Permethrin 1% Creme Rinse for the Treatment of Pediculus HumanusVar Capitis Infestation” published in the Journal “PediatrDermatol” in September 2019, permethrin 1% cream rinse (Nix) has been tested as a treatment for Pediculus humanusvar capitis ( head lice) in a randomized, double-blind, placebo-controlled study. As a positive control, a third arm of the study included a non-randomized, but blinded, treatment with 1% lindane shampoo (Kwell). 14 days after treatment, 97% of the permethrin-treated patients were lice-free compared to 6% of the placebo-treated patients (P less than 0.001) and 43% of the lindane-treated group.
According to the same study, permethrin was 70% ovicidal versus 14% for placebo (P less than 0.001) and 45% for lindane. No adverse effects were noted during this study. Permethrin 1% has demonstrated high pediculicidal and ovicidal activities which, combined with its low mammalian toxicity, residual activity and cosmetic properties, make it an excellent treatment for pediculosis capitis. These data show the significant use of permethrin in the treatment of head lice.
Therefore, the demand for Permethrin is expected to rise which will significantly boost the overall target market over the study period.
North America dominates the market and is expected to do the same during the forecast period
North America is expected to dominate the overall head lice treatment market, throughout the forecast period. The larger share is mainly due to the presence of a larger pool of infestation and the increase in the population of children.
For example, the United States Census Bureau in its 2020 census showed that the number of children under the age of 18 was 73.1 million in 2020. The largest pool of infestation and the increase in child population attribute factors for the growth of the market in the United States. States.
Additionally, increasing product approvals are also contributing to the growth of the market. For example, in July 2020, the United States Food and Drug Administration (FDA) approved the use of Xeglyze, a drug used to treat head lice in patients aged 6 months and older. The FDA approved the drug after a clinical trial studying the drug’s effectiveness in preventing head lice infestation. The study showed that around 80% of patients treated with Xeglyze had no live head lice.
Thus, owing to the developments mentioned above, the market is expected to witness significant growth over the forecast period.
The lice treatment market is moderately competitive. A few of the crucial approaches followed by the players operating in the market were product advancement, invention, acquisitions, and mergers. Some of the companies currently dominating the market are Alliance Pharmaceuticals Ltd., Prestige Consumer Healthcare Inc., GlaxoSmithKline plc, Oystershell Consumer Health, Inc., and Perrigo Company plc.
The Market Estimate (ME) sheet in Excel format
3 months of analyst support
Read the full report: https://www.reportlinker.com/p06272906/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001